ITI MF

CATEGORY OF SCHEME	Sectoral/Thematic
INVESTMENT OBJECTIVE	The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Inception Date (Date of Allotment):	08-Nov-21
Benchmark:	Nifty Healthcare TRI
Minimum Application Amount:	Rs.5,000/- and in multiples of Rs. 1/- thereafter
Load Structure:	Entry Load: Nil Exit Load: 1% if redeemed or switched out on or before completion of 12 months from the date of allotment of units · Nil, if redeemed or switched out after completion of 12 months from the date of allotment of units.
Total Expense Ratio (TER):	Including Additional Expenses and Goods and Service Tax on Management Fees Regular Plan: 2.35% Direct Plan: 0.47%
Fund Manager	Mr. Rohan Korde (Since 08-Nov-21) Total Experience: 17 years Mr. Dhimant Shah (Since 01 December 2022) Total Experience : 26 years

AUM (in Rs. Cr):	220.85
AAUM (in Rs. Cr):	219.54
% of top 5 holdings:	40.32%
% of top 10 holdings:	59.20%
No. of scrips:	39

Standard Deviation^:	15.61%
Beta^:	0.90
*Sharpe Ratio^:**	0.82
Average P/B	10.03
Average P/E	46.25
Portfolio Turnover Ratio	0.57
^Computed for the 3-yr period ended May 30, 2025. Based on monthly return. * Risk free rate: 5.86 (Source: FIMMDA MIBOR)

	Regular Plan (in Rs.)	Direct Plan (in Rs.)
Growth:	15.9141	17.1119
IDCW:	15.9141	17.1119

Name of the Instrument	% to NAV	% to NAV Derivatives
Equity & Equity Related Total	99.71
Chemicals	4.56
Sumitomo Chemical India Limited	1.43
UPL Limited	1.14
Linde India Limited	1.07
SRF Limited	0.93
Diversified	0.32
TTK Healthcare Limited	0.32
Healthcare	93.54
Sun Pharmaceutical Industries Limited	15.18
Divi's Laboratories Limited	9.12
Max Healthcare Institute Limited	5.42
Lupin Limited	5.40
Apollo Hospitals Enterprise Limited	5.19
Cohance Lifesciences Limited	4.84
Aurobindo Pharma Limited	3.93
Torrent Pharmaceuticals Limited	3.91
Aster DM Healthcare Limited	3.15
Mankind Pharma Limited	3.04
Alkem Laboratories Limited	2.87
Fortis Healthcare Limited	2.43
Abbott India Limited	2.33
Wockhardt Limited	2.28
Granules India Limited	2.11
Neuland Laboratories Limited	1.98
FDC Limited	1.55
Healthcare Global Enterprises Limited	1.55
Supriya Lifescience Limited	1.48
Rainbow Childrens Medicare Limited	1.28
JB Chemicals & Pharmaceuticals Limited	1.23
Vijaya Diagnostic Centre Limited	1.23
Shilpa Medicare Limited	1.22
Dr. Reddy's Laboratories Limited	1.22
Gland Pharma Limited	1.18
GlaxoSmithKline Pharmaceuticals Limited	1.18
Onesource Specialty Pharma Limited	1.09
Caplin Point Laboratories Limited	1.08
Orchid Pharma Limited	1.03
Cipla Limited	1.02
Sai Life Sciences Limited	1.02
Strides Pharma Science Limited	1.01
Laurus Labs Limited	0.97
Information Technology	1.29
Sagility India Limited	1.29
Short Term Debt & Net Current Assets	0.29

Top Ten Holdings

Period	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Benchmark (Rs)	Fund (Rs)	Additional Benchmark Returns (Rs)
Regular - Growth
Last 1 Year	20.24%	18.49%	11.11%	12,018	11,844	11,108
Last 3 Years	21.67%	22.01%	15.56%	18,013	18,161	15,432
Since Inception	13.95%	15.04%	10.50%	15,914	16,464	14,268
Direct - Growth
Last 1 Year	22.51%	18.49%	11.11%	12,244	11,844	11,108
Last 3 Years	24.09%	22.01%	15.56%	19,110	18,161	15,432
Since Inception	16.29%	15.04%	10.50%	17,112	16,464	14,268

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. The performance data for 5 years period has not been provided, since scheme is in existence for less than 5 years. In case, the start / end date of the concerned period is a non-business date (NBD), the NAV of the previous date is considered for computation of returns. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. Fund Managers: Mr. Rohan Korde (Managing since 08-Nov-21) and Mr. Dhimant Shah (Managing since 01-December-22). Inception date of the scheme is (08-Nov-2021). Face Value per unit: Rs. 10. ITI Pharma & Healthcare Fund NAV as on May 30, 2025: Rs. 15.9141 (Regular Growth Option), Rs. 17.1119 (Direct Growth Option)

Period	Amount Invested	Fund Returns (%)	Benchmark Returns (%)	Additional Benchmark Returns (%)	Fund Value ()	Benchmark Value ()	Additional Benchmark Value ()
Regular - Growth
Last 1 Year	1,20,000	2.34%	3.16%	6.98%	1,21,491	1,22,011	1,24,417
Last 3 Years	3,60,000	21.72%	22.80%	14.67%	4,93,898	5,01,326	4,47,338
Since Inception	4,30,000	19.82%	20.76%	13.96%	6,08,862	6,18,554	5,50,965
Direct - Growth
Last 1 Year	1,20,000	4.29%	3.16%	6.98%	1,22,725	1,22,011	1,24,417
Last3 Years	3,60,000	24.15%	22.80%	14.67%	5,10,670	5,01,326	4,47,338
Since Inception	4,30,000	22.20%	20.76%	13.96%	6,33,618	6,18,554	5,50,965

Past performance may or may not be sustained in future and is not a guarantee of any future returns, and should not be used as a basis of comparison with other investments. Different Plans i.e. Regular Plan and Direct Plan under the scheme have different expense structure. Benchmark: Nifty Healthcare TRI Additional Benchmark: Nifty 50 TRI. For SIP returns, monthly investment of Rs.10,000 invested on the 1st business day of every month has been considered. CAGR Returns (%) are computed after accounting for the cash flow by using the XIRR method (investment internal rate of return).